Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving profitability. Future growth is anticipated from capacity expansions and new product lines. The company’s contract development and manufacturing business is also expanding. Investors are watching Gland Pharma’s growth prospects.
Earnings growth to stay robust at 14–16%; IT correction a buying opportunity: Vikas Khemani
India’s IT sector is poised for a comeback, with AI expected to boost, not hinder, growth. Vikas Khemani of Carnelian Asset Management sees excessive pessimism,